These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17898711)

  • 1. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects.
    Bertilsson L
    Clin Pharmacol Ther; 2007 Nov; 82(5):606-9. PubMed ID: 17898711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
    de Leon J; Susce MT; Murray-Carmichael E
    Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
    Masimirembwa CM; Hasler JA
    Brain Res Bull; 1997; 44(5):561-71. PubMed ID: 9365799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approach to predict the contribution of cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage: the effect of the expression of cytochrome b(5) with recombinant P450 enzymes.
    Emoto C; Iwasaki K
    Xenobiotica; 2007 Sep; 37(9):986-99. PubMed ID: 17896325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
    Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
    J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and psychopharmacotherapy.
    Poolsup N; Li Wan Po A; Knight TL
    J Clin Pharm Ther; 2000 Jun; 25(3):197-220. PubMed ID: 10886465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seizures and myoclonus associated with antidepressant treatment: assessment of potential risk factors, including CYP2D6 and CYP2C19 polymorphisms, and treatment with CYP2D6 inhibitors.
    Spigset O; Hedenmalm K; Dahl ML; Wiholm BE; Dahlqvist R
    Acta Psychiatr Scand; 1997 Nov; 96(5):379-84. PubMed ID: 9395157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry.
    Brøsen K
    Ther Drug Monit; 1996 Aug; 18(4):393-6. PubMed ID: 8857557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
    Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
    Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
    Caraco Y; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
    Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
    Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I; Oscarson M; Yue QY; Bertilsson L; Sjöqvist F; Ingelman-Sundberg M
    Mol Pharmacol; 1994 Sep; 46(3):452-9. PubMed ID: 7935325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.
    Anderson GD
    J Gend Specif Med; 2002; 5(1):25-33. PubMed ID: 11859684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population.
    Aynacioglu AS; Sachse C; Bozkurt A; Kortunay S; Nacak M; Schröder T; Kayaalp SO; Roots I; Brockmöller J
    Clin Pharmacol Ther; 1999 Aug; 66(2):185-92. PubMed ID: 10460072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genetic polymorphism of drug metabolizing enzymes].
    Yokoi T; Kamataki T
    Seikagaku; 1997 Oct; 69(10):1196-9. PubMed ID: 9431010
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetically variable metabolism of antidepressants and neuroleptic drugs in man.
    Dahl ML; Bertilsson L
    Pharmacogenetics; 1993 Apr; 3(2):61-70. PubMed ID: 8100166
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.